Buy Rating Reiterated on Faron: De-Risked Bexmarilimab Strategy in High-Risk MDS and Upside from Solid Tumor Expansion

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Faron Pharmaceuticals Oy, with a price target of £10.00.

Patrick Trucchio has given his Buy rating due to a combination of factors, including Faron’s strategic repositioning of bexmarilimab in higher-risk MDS and a clearer regulatory pathway. The company’s staged development plan—starting with a randomized Phase 2 trial and progressing to a Phase 3 study using complete response and event-free survival instead of overall survival—aims to lower trial risk, improve capital efficiency, and potentially accelerate time to approval.

He also highlights that this approach aligns with recent FDA guidance and contrasts favorably with failed late-stage MDS studies that relied on overall survival as the primary endpoint. In addition, Faron’s push into solid tumors through multiple investigator-initiated trials, along with upcoming proof-of-concept data, creates meaningful upside optionality and partnership or M&A appeal, supporting his reiterated Buy rating and price target.

Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of FARN in relation to earlier this year.